Press Releases

Topics:
  TITLE DATE  
 
 

Nymox Fexapotide Symposium and Panel Discussion at American Urological Association South Central Sectional Annual Meeting in Naples FL

2017-11-27

 
 
Topic:  R&D: BPH (enlarged prostate) Treatments
 
 

Nymox Pharmaceutical Corporation is pleased to report on the Symposium which was held on Fexapotide Triflutate studies at the Annual Meeting of the American Urological Association, South Central Section in Naples, November 27.

 
 
 

Nymox Fexapotide Symposium and Panel Discussion at American Urological Association North Central Sectional Annual Meeting in Scottsdale

2017-11-16

 
 
Topic:  R&D: BPH (enlarged prostate) Treatments
 
 

Nymox Pharmaceutical Corporation is pleased to report on the Symposium which was held on Fexapotide Triflutate studies at the Annual Meeting of the American Urological Association, North Central Section in Scottsdale, November 15.

 
 
 

Symposium and Panel Discussion on Nymox's Fexapotide To Be Held at American Urological Association North Central Section Annual Meeting in Scottsdale AZ November 15

2017-11-10

 
 
Topic:  R&D: BPH (enlarged prostate) Treatments
 
 

Nymox Pharmaceutical Corporation is pleased to report that a Symposium on Fexapotide Triflutate studies will be held at the Annual Meeting of the American Urological Association North Central Section, in Scottsdale AZ next week.

 
 
 

Nymox Reports on Symposium, Panel Discussion and Podium Presentation on Fexapotide at American Urological Association New York Section Annual Meeting in Havana

2017-11-07

 
 
Topic:  R&D: BPH (enlarged prostate) Treatments
 
 

Nymox Pharmaceutical Corporation is pleased to report on the two data presentations which were held on Fexapotide Triflutate studies at the Annual Meeting of the American Urological Association, New York Section in Havana, November 6.

 
 
 

Nymox Announces Two Data Presentations for Company's BPH Drug at New York American Urological Association Meeting November 6

2017-10-26

 
 
Topic:  R&D: BPH (enlarged prostate) Treatments
 
 

Nymox Pharmaceutical Corporation is pleased to announce that two data presentations of the Company's new drug Fexapotide Triflutate will be held at the November meeting of the American Urological Association, New York Section.

 
 
 

Nymox Reports on Symposium, Panel Discussion with Abstract on Fexapotide at American Urological Association Northeast Sectional Annual Meeting in Savannah

2017-10-13

 
 
Topic:  R&D: BPH (enlarged prostate) Treatments
 
 

Nymox Pharmaceutical Corporation is pleased to report on the Symposium which was held on Fexapotide Triflutate studies at the Annual Meeting of the American Urological Association, Northeast Section in Savannah, October 12 at 4 pm.

 
 
 

Nymox Reports on Symposium and Panel Discussion on Fexapotide at American Urological Association Northeast Sectional Annual Meeting in Savannah October 12

2017-10-10

 
 
Topic:  R&D: BPH (enlarged prostate) Treatments
 
 

Nymox Pharmaceutical Corporation is pleased to report on the Symposium on Fexapotide Triflutate studies to be held at the Annual Meeting of the American Urological Association Northeastern Section, in Savannah GA this week.

 
 
 

Nymox Announces October 12 Symposium for Company's BPH Drug at American Urological Association Meeting

2017-09-25

 
 
Topic:  R&D: BPH (enlarged prostate) Treatments
 
 

Nymox Pharmaceutical Corporation is pleased to announce that an important large symposium and panel assessment of the Company's new drug Fexapotide Triflutate will be held at the October meeting of the American Urological Association, Northeast Section.

 
 
 

Nymox Announces New Symposium for Company's BPH Drug at American Urological Association Meeting October 5

2017-09-14

 
 
Topic:  R&D: BPH (enlarged prostate) Treatments
 
 

Nymox Pharmaceutical Corporation is pleased to announce that an important large symposium and panel assessment of the Company's new drug Fexapotide Triflutate will be held at the October meeting of the American Urological Association, South Central Section.

 
 
 

Nymox Application Validated: Nymox Announces Validation by the European Member States of European Marketing Authorization Application for Fexapotide Triflutate for Benign Prostatic Hyperplasia

2017-09-14

 
 
Topic:  R&D: BPH (enlarged prostate) Treatments
 
 

Nymox Pharmaceutical Corporation is pleased to announce today that the European Member States for Nymox's Marketing Authorization Application (MAA) for Fexapotide Triflutate for the treatment of benign prostatic hyperplasia (BPH, prostate enlargement) have accepted the Company’s MAA.

 
  Total   385   Records   First   Previous   1 of 39   Next   Last      Go